25 Apr 07 Ranbaxy gets FDA approval and a 180 day monopoly for pravastatin sodium drug
Ranbaxy today announced that it obtained FDA approval and a 180 day monopoly for its pravastatin sodium drug. After this announcement was made, Ranbaxy shares zoomed by 4% to Rs. 364 on huge volumes of over 5 lakh shares, in the BSE. Ranbaxy was the top gainer today in the Sensex pack.
Related Posts
Leave a Comment
